Global Antibiotic Resistance Market Worth Around USD 12.11 billion by 2026: Acumen Research and Consulting

The global antibiotic resistance market is anticipated to grow at considerable CAGR over 5.5% over the forecast period and reach US$ 12.11 Bn by 2026.  According to the report, the global market will continue to be influenced by a range of macroeconomic and regulatory factors. Emergence of multi-drug resistant pathogens, growing need to prevent antibiotic effects and rise in incidences of chronic and infectious diseases across the globe have boosted the growth of the global antibiotic resistance market. 

 

 

 

Complicated urinary tract infection (cUTI) is expected to be the leading segment of the global antibiotic resistance market during the forecast period, owing to the the high cost of treatment and limited treatment alternatives for gram-negative pathogens which causes majority of infections.Complicated urinary tract infection (cUTI) segment is anticipated to expand at considerable CAGR throughout the forecast period from 2018 to 2026. Moreover, gram-negative pathogens restricts the recently authorized advanced therapies such as Merck’s Zerbaxa, Allergan’s Avycaz and Vabomere, due to lack of low cost treatment options. Antibiotic-resistant gram-positive bacteria causes larger number of infections. Hence, the demand for antibiotic resistance for such diseases is increasing rapidly. Additionally, the cost of gram-negative infection therapy are higher than that of gram-positive infections as gram-negative therapy due to the availability of number of treatments for gram-positive therapy.

 

 

 

Increasing percentage of infectious diseases have led to launch of various antibiotic drugs, thereby propelling the growth of the market globally. Growing geriatric population across developed as well as developing regions is bolstering the growth of the global antibiotic resistance market. Growing need to reduce or eliminate the effectiveness of antibiotics is boosting the demand for antibiotic drugs. Various governments are taking initiatives towards introducing clinically advanced antibiotic drugs in order to overcome the bacterial infections or diseases. Furthermore, technological advancements through drug formulations are expected to increase the number of drug launches globally. Growing initiatives by various governments for the commercialization of therapies is resulting in the clinical trials and new drug development. For instance, the Food and Drug Administration (FDA) launched several initiatives such as drug labeling regulations, emphasizing the prudent use of antibiotics to address infectious diseases.

 

Additionally, multiple prominent biotechnology companies are entering into strategic collaborations in order to make considerable investments in drug discovery.

 

 

Geographically, the global antibiotic resistance market has been divided into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for largest market share in 2017 due to the numerous drug launches and presence of large number of pharmaceutical companies in the region. North America is anticipated to grow at significant CAGR over the forecast period owing to the factors such as clinical innovations and high treatment cost. Various organizations from the region are entering into strategic collaborations to make considerable investments in drug discovery, resulting in the growth of the market. In 2016, National Institute of Allergy and Infectious Diseases (NIAID) in partnership with BARDA launched CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) in order to focus on clinical development. Owing to the prevalence of various infectious diseases and increase in population, Asia Pacific is expected to grow at significant rate during the forecast period.

 

 

The company profiling of key players in the global antibiotic resistance market includes company overview, major business strategies and revenues. The key players of the market are TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences  and BioVersys GmbH. Industry participant battle on the basis of price, new innovated product launch, and expanding market presence.